Agios Pharmaceuticals Valuation Multiples

Agios Pharmaceuticals Overview

About Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Founded

2007

HQ

Employees

540

Website

agios.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $65M

EBITDA: ($461M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Agios Pharmaceuticals Financials

Agios Pharmaceuticals reported last 12-month revenue of $65M and negative EBITDA of ($461M).

In the same LTM period, Agios Pharmaceuticals generated $58M in gross profit, ($461M) in EBITDA losses, and had net loss of ($407M).

Agios Pharmaceuticals P&L

In the most recent fiscal year, Agios Pharmaceuticals reported revenue of $54M and EBITDA of ($467M).

Agios Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals has current market cap of $2B, and enterprise value of $1B.

Agios Pharmaceuticals' stock price is $32.92.

Agios Pharmaceuticals Valuation Multiples

Agios Pharmaceuticals trades at 17.3x EV/Revenue multiple, and (2.4x) EV/EBITDA.

Agios Pharmaceuticals Financial Valuation Multiples

As of April 12, 2026, Agios Pharmaceuticals has market cap of $2B and EV of $1B.

Equity research analysts estimate Agios Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Agios Pharmaceuticals has a P/E ratio of (4.7x).

Agios Pharmaceuticals Margins & Growth Rates

Agios Pharmaceuticals' revenue in the last 12 month grew by 107%.

Agios Pharmaceuticals' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Agios Pharmaceuticals' rule of 40 is (413%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Agios Pharmaceuticals' rule of X is (307%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Agios Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Agios Pharmaceuticals M&A Activity

Agios Pharmaceuticals acquired XXX companies to date.

Last acquisition by Agios Pharmaceuticals was on XXXXXXXX, XXXXX. Agios Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Agios Pharmaceuticals Investment Activity

Agios Pharmaceuticals invested in XXX companies to date.

Agios Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Agios Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).